This RespiVerse Forum integrates science, technology and talent to identify key clinical challenges in the field of respiratory medicine and develop scientific content that will enhance the knowledge and professional practice of respiratory medicine specialists.
“For decades, we have been pioneering new treatment solutions, setting the standard for next-generation treatments and developing future respiratory medicines, with the aim of positively impacting hundreds of millions of respiratory patients globally,” said Dr Gur Levy, Respiratory Medicine Specialist at GSK.
In collaboration with international specialists and experts, GSK has created a groundbreaking program that has improved clinical practice and outcomes for millions of patients with respiratory diseases.
“We research and develop a portfolio of vaccines, targeted biologics/therapeutics, and innovative inhaled respiratory medicines to improve outcomes and enhance the quality of life of people with asthma, COPD, and RSV,” said Dr. Levy.
